In a Phase II clinical trial conducted by Redman et al., 26 patients with untreated microsatellite-stable (MSS) metastatic CRC were randomized to receive either the standard-of-care (SOC) regimen (avelumab, mFOLFOX6, and bevacizumab) alone or the SOC regimen combined with the Ad5 [E1-, E2b-]-CEA (AdCEA) vaccine [149]. Here, CEACAM5 is linked to colorectal carcinoma.